Source-Connect 4 Becomes First metadata-connected Dolby® Atmos remote review & approval tool
prnewswire.com
Want to monitor CLRB?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor CLRBcellectar biosciences is developing phospholipid drug conjugates (pdcs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. cellectar's pdc platform is based on the company's proprietary phospholipid ether analogs. these novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers.